Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data from the TRESR RP-3500 Phase 1/2 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL, March 08, 2022–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discovery and development of novel therapeutics, announced today that it has been selected for an oral presentation of clinical data from its ongoing TRESR Phase 1/2 trial of RP-3500 and a poster presentation of initial data Discovery and Validation of the New Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand the allelic status of STEP2 genes at the upcoming 2022 AACR Annual Meeting, to be held in New Orleans from 8 to April 13, 2022.

Details of the oral presentation on the results of the RP-3500 Phase 1/2 TRESR trial:
Genomic and pathological determinants of response to RP-3500, an ataxia telangiectasia and Rad3 (ATRi) inhibitor, in patients (pts) with DNA damage repair (DDR) mutant tumors with loss of function (LOF) in phase 1/ 2 TRESR test
Presenter: Dr. Timothy Yap, MBBS, Ph.D., FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
Abstract number: CT030
Session title: Minisymposium on Clinical Trials – Patient Selection Strategies for Molecularly Targeted Agents in Clinical Trials
Date hour : Monday, April 11, 2022 from 2:30 p.m. to 4:30 p.m. CT

SNiPDx Panel Presentation Details for Synthetic Lethal Drug Discovery:
Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded (FFPE) tumor samples using a novel error-corrected tumor sequencing-only panel
Presenter: Dominik Glodzik, Ph.D., Repare Therapeutics, Instructor in Biomedical Informatics, Harvard Medical School
Abstract number: 2801
Session title: Diagnostic biomarkers
Date hour : Tuesday, April 12, 2022 at 9:00 a.m. CT

About Repare Therapeutics SNIPRx® Platform

Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that uses proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and corresponding patients who are most likely to benefit from the company’s therapies based on the genetic profile of their tumours. Repare’s platform enables the development of precision therapies in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target these tumors in patients most likely to obtain clinical benefit from the products. resulting candidates.

About Repaire Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapies. The company uses its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly-targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development , a Polθ inhibitor program, as well as eight other early-stage preclinical programs. For more information, visit

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

See the source version on


Repair contact:
Steve Forte
Financial director
Therapeutic Den Inc.
[email protected]

Kimberly Minarovich
Slang Partners
[email protected]

David Rosen
Slang Partners
[email protected]

Comments are closed.